Vaxess Technologies, Inc.
October 18, 2023
Company Description: Vaxess is an RA Capital-backed, clinical-stage company bringing healthcare out of the clinic with the MIMIX Smart Release patch platform. The MIMIX platform, developed at MIT, uses breakthrough immune-activating biology to enable best-in-class vaccines and immunotherapies in a shelf-stable, self-applied format. The company’s lead program, a seasonal influenza vaccine, just read out strong Phase I interim results. The company is building a pipeline of products on the MIMIX platform, including a collaboration with Astra Zeneca.
CEO/Top Company Official
Lead Product in Development
MIMIX-Flu, the first seasonal influenza vaccine intended for home-based administration. The product completed a successful Phase I trial in early 2023.
Development Phase of Primary Product